A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...
ViiV Healthcare’s combination injectable human immunodeficiency virus (HIV) medication was preferred over a daily tablet in treatment-naïve patients in a Phase IIIb trial. A global specialist in HIV ...
The Food and Drug Administration has given the green light to ViiV Healthcare for its new once-monthly HIV treatment. The company's Cabenuva (cabotegravir and rilpivirine, injectable formulation) was ...
Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) across a broad range of populations Implementation science data for ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
Share on Pinterest Lenacapavir is a twice-yearly injection to prevent HIV that could improve adherence rates compared to other PrEP medications. d3sign/Getty Images The WHO issued a global ...
Implementation science data for Apretude (cabotegravir long-acting (CAB LA) for PrEP) demonstrate 95% of participants were happy they switched from oral PrEP to CAB LA Jean van Wyk, MBChB, MFPM, Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results